摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Boc-3-甲氨基吡咯烷 | 454712-26-6

中文名称
1-Boc-3-甲氨基吡咯烷
中文别名
1-BOC-3-甲氨基吡咯;3-甲氨基吡咯烷-1-甲酸叔丁酯;1-BOC-3-甲氨基吡咯烷;1-Boc-3-(甲氨基)吡咯烷
英文名称
tert-butyl 3-(methylamino)pyrrolidine-1-carboxylate
英文别名
1-Boc-3-methylaminopyrrolidine
1-Boc-3-甲氨基吡咯烷化学式
CAS
454712-26-6
化学式
C10H20N2O2
mdl
MFCD06656606
分子量
200.281
InChiKey
OKUCEQDKBKYEJY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    269 °C
  • 密度:
    1.03
  • 闪点:
    117 °C

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    41.6
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    T,N
  • 安全说明:
    S45,S61
  • 危险类别码:
    R25,R50
  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温。

SDS

SDS:1833213603f83f4d10cb851d3c942427
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-BOC-3-Methylaminopyrrolidine
Synonyms: tert-Butyl 3-(methylamino)pyrrolidine-1-carboxylate

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
P273: Avoid release to the environment
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician

Section 3. Composition/information on ingredients.
Ingredient name: 1-BOC-3-Methylaminopyrrolidine
CAS number: 454712-26-6

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H20N2O2
Molecular weight: 200.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-Boc-3-甲氨基吡咯烷磺酰氯三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 2.0h, 生成 tert‐butyl 3‐[(chlorosulfonyl)(methyl)amino]pyrrolidine‐1‐carboxylate
    参考文献:
    名称:
    一类IDO抑制剂及其应用
    摘要:
    本发明实施例提供了通式(I)的化合物或其药学上可接受的盐、立体异构体、互变异构形式、多晶型物、溶剂合物、前药、代谢物或同位素衍生物,其中取代基R1、R2、R0的定义如说明书所记载;本发明所合成的小分子IDO抑制剂药效作用显著,安全性高,将有希望成为一类新型的抗肿瘤药物。
    公开号:
    CN109897011A
  • 作为产物:
    描述:
    Tert-butyl 3-[methyl-(2-nitrophenyl)sulfonylamino]pyrrolidine-1-carboxylate 在 potassium carbonate 作用下, 以 乙腈 为溶剂, 反应 12.0h, 生成 1-Boc-3-甲氨基吡咯烷
    参考文献:
    名称:
    发现了一种新型的双环化合物DS54360155,它是一种口服有效的止痛药,没有mu阿片类受体激动剂活性。
    摘要:
    我们合成了天然生物碱,可可定的衍生物,并在口服后在ddY小鼠中的乙酸诱导的扭体试验和福尔马林试验中评估了这些衍生物。结果,我们确定了(5 S)-6-甲基-1,3,4,5,6,8-六氢-7H-2,5-甲基[1,5]重氮基[7,8-b]吲哚-7-硫酸盐15a(DS54360155)具有独特的原始双环骨架,比可可啶具有更强的镇痛作用。此外,15a没有表现出μ阿片受体激动剂活性。
    DOI:
    10.1016/j.bmcl.2019.126748
点击查看最新优质反应信息

文献信息

  • [EN] ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS<br/>[FR] ACIDES ALKYLBORONIQUES EN TANT QU'INHIBITEURS D'ARGINASE
    申请人:GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD
    公开号:WO2020160707A1
    公开(公告)日:2020-08-13
    Provided are alkylboronic acids as arginase inhibitors represented by formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof and a pharmaceutical composition comprising said compounds.
    提供的是以化学式(I)表示的烷基硼酸作为精氨酸酶抑制剂,或其药用可接受的盐、立体异构体、互变异构体或前药,以及包含该化合物的药物组合物。
  • TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
    申请人:Merck Patent GmbH
    公开号:US20160376283A1
    公开(公告)日:2016-12-29
    The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.
    本发明涉及式I化合物及其药用可接受的组合物,用作TBK/IKKε抑制剂。
  • INDOLE CARBOXAMIDE COMPOUNDS
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20160115126A1
    公开(公告)日:2016-04-28
    Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR 4 or N; R 1 , R 2 , R 3 , R 4 , and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    揭示了Formula (I)的化合物: 或其盐,其中:X为CR 4 或N;R 1 ,R 2 ,R 3 ,R 4 和A在此处定义。还揭示了使用这些化合物作为Bruton's酪氨酸激酶(Btk)抑制剂的方法,以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓各种治疗领域的疾病或疾病的进展方面非常有用,如自身免疫疾病和血管疾病。
  • [EN] HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
    申请人:ARTIOS PHARMA LTD
    公开号:WO2021028643A1
    公开(公告)日:2021-02-18
    The application relates to heterocyclic amide derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation. (Formula (I))
    该申请涉及杂环酰胺衍生物及其在癌症治疗和预防中的应用,以及含有这些衍生物的组合物和其制备方法。(化学式(I))
  • [EN] IMIDAZOLOPYRAZINE COMPOUNDS FOR IRE1 INHIBITION<br/>[FR] COMPOSÉS D'IMIDAZOLOPYRAZINE POUR INHIBITION D'IRE1
    申请人:OPTIKIRA LLC
    公开号:WO2020176761A1
    公开(公告)日:2020-09-03
    The present invention provides novel imidazolopyridine compounds compounds, compositions and methods for treating or preventing an IRE1 α-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.
    本发明提供了用于治疗或预防IRE1α相关疾病或紊乱的新型咪唑吡啶化合物、组合物和方法。在某些实施例中,所述疾病或紊乱选自神经退行性疾病、脱髓鞘疾病、癌症、眼部疾病、纤维化疾病和糖尿病等组。
查看更多

同类化合物

(2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁 阿维巴坦中间体1 阿曲生坦中间体 阿曲生坦 间甲氧基苯乙腈 铂(2+)羟基乙酸酯-吡咯烷-3-胺(1:1:1) 钾2-氧代吡咯烷-1-磺酸酯 钠1-[(9E)-9-十八碳烯酰基氧基]-2,5-二氧代-3-吡咯烷磺酸酯 金刚烷-1-基(吡咯烷-1-基)甲酮 酸-1-吡咯烷-1,4-氨基-2-甲基-1,1,1-二甲基乙基酯,(2S,4R)- 酚丙氢吡咯 试剂3-Mercaptopropanyl-N-hydroxysuccinimideester 西他利酮 血红素酸 螺虫乙酯残留代谢物Mono-Hydroxy 萘吡坦